Millennium, J&JPRD Begin Phase III Velcade Trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Millennium Pharmaceuticals and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) initiated a Phase III trial of Velcade in combination with Rituxan in patients with relapsed or refractory follicular lymphoma, a subtype of non-Hodgkin’s lymphoma (NHL). This study builds on clinical data observed in previous trials of Velcade that showed high objective response rates and a favorable safety profile across a variety of lymphomas. The Phase III study is expected ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters